XML 74 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Note 4 - Collaboration Revenue (Details Textual)
$ / shares in Units, ¥ in Billions
 1 Months Ended 12 Months Ended 31 Months Ended
Jun. 13, 2022
USD ($)
shares
Nov. 20, 2020
USD ($)
Nov. 12, 2020
$ / shares
shares
Jun. 30, 2022
USD ($)
shares
Nov. 30, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Nov. 12, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2021
CNY (¥)
Revenue from Contract with Customer, Including Assessed Tax           $ 1,751,000 $ 1,351,000 $ 1,351,000        
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member] | Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]                        
Collaboration Agreement, Upfront Cash Payment                     $ 31,039,000 ¥ 0.2
Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]                        
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value $ 3,763,000               $ 5,267,000      
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]                        
Collaborative Arrangement, Upfront Cash Payment   $ 9,455,000     $ 10,000,000              
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer           2,000,000            
Derivative Liability, Total $ 1,237,000               278,000      
Proceeds from Issuance or Sale of Equity, Total   $ 15,000,000             $ 15,000,000      
Revenue from Contract with Customer, Including Assessed Tax           1,751,000 1,351,000          
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received                     108,638,000 0.7
Collaboration Agreement, Maximum Commercial Milestones to be Received                     $ 62,079,000 ¥ 0.4
Revenue from Contract with Customer, Excluding Assessed Tax           $ 0 $ 0 $ 0        
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Convertible Preferred Shares [Member]                        
Stock Issued for Transfer of Assets, Shares (in shares) | shares     9,631,941                  
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Preferred Shares [Member]                        
Stock Issued During Period, Shares, New Issues (in shares) | shares     1,194,030                  
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]                        
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,990,000   1,990,000 1,990,000                
Shares Issued, Price Per Share (in dollars per share) | $ / shares     $ 2.5125                  
Stock Issued During Period, Value, New Issues $ 5,000,000     $ 5,000,000                
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member]                        
Stock Issued During Period, Shares, New Issues (in shares) | shares                   1,990,000    
Shares Issued, Price Per Share (in dollars per share) | $ / shares                   $ 2.5125    
Stock Issued During Period, Value, New Issues                   $ 1,990,000    
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Maximum [Member]                        
Collaborative Arrangement, Equity Investment         $ 780,000,000